Entering text into the input field will update the search result below

NeoGenomics joins Thermo Fisher's companion diagnostic center of excellence program with the launch of Oncomine Dx Target test

Dec. 05, 2017 7:37 AM ETNeoGenomics, Inc. (NEO) StockBy: SA News Team
  • NeoGenomics (NASDAQ:NEO) signs an agreement with Thermo Fisher Scientific (TMO) to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. NeoGenomics is one of the first laboratories to offer the newly FDA-approved Oncomine Dx Target Test for Non-Small Cell Lung Cancer (NSCLC). This methodology allows rapid analysis of samples compared to previously approved testing approaches.
  • NeoGenomics' Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA. The test evaluates 23 genes associated with NSCLC.

Recommended For You

More Trending News

About NEO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NEO--
NeoGenomics, Inc.